Clinical Practice of AECOPD Management in China
A Non Interventional, Retrospective Study on AECOPD Treatment Status in China
1 other identifier
observational
5,095
1 country
13
Brief Summary
The purpose of this study is observe clinical practice including glucocorticoids treatment in AECOPD in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2014
Shorter than P25 for all trials
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 24, 2014
CompletedFirst Posted
Study publicly available on registry
January 31, 2014
CompletedStudy Start
First participant enrolled
February 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedJune 15, 2016
June 1, 2016
6 months
January 24, 2014
June 14, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of glucocorticoids treatment for AECOPD
day 1 to up to 30 days (Hospital discharge)
Secondary Outcomes (9)
Percentage of oral /intravenous/ inhaled steroid therapy in patients treated with glucocorticoids, mean dosage, regimen and treatment duration via different administration route in hospital
day 1 to up to 30 days (Hospital discharge)
Percentage of antibiotics treatment for AECOPD by clinicians during the hospitalization.
day 1 to up to 30 days (Hospital discharge)
Mortality caused by AECOPD and recorded as primary cause of death by clinicians
day 1 to up to 30 days (Hospital discharge)
Percentage of antibiotics treatment via different administration route for AECOPD, mean treatment duration via different administration route in hospital
day 1 to up to 30 days (Hospital discharge)
Endotracheal intubation rate in treatment of AECOPD
day 1 to up to 30 days (Hospital discharge)
- +4 more secondary outcomes
Other Outcomes (5)
Demographic data
day 1
Year of COPD diagnosis
day 1
Any other significant medical condition or co-morbidities
day 1
- +2 more other outcomes
Eligibility Criteria
The patient population will be ≥40 years of age, received hospitalization due to AECOPD since Sep, 2013. The patients should be diagnosed by GOLD 2013 as COPD at least 3 months before AECOPD based on treating physician judgment.
You may qualify if:
- ≥40 years old
- Hospitalization treatment due to AECOPD since Sep, 2013
- Diagnosed by GOLD 2013 as COPD at least 3 months before AECOPD based on treating physician's judgment
- Provided informed consent or informed consent waiver
You may not qualify if:
- Participation in any interventional clinical study within 3 months before being recruited in the study.
- Ongoing AECOPD during recruitment timeline
- The patients whose symptoms haven't recovered and then discharge by themselves
- The primary diagnosis of hospitalization is not AECOPD
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (13)
Research Site
Hefei, Anhui, China
Research Site
Beijing, Beijing Municipality, China
Research Site
Langfang, Hebei, China
Research Site
Baotou, Inner Mongolia, China
Research Site
Hohhot, Inner Mongolia, China
Research Site
Yinchuan, Ningxia, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Taiyuan, Shanxi, China
Research Site
Xi’an, Shanxi, China
Research Site
Beijing, China
Research Site
Guangzhou, China
Research Site
Shanghai, China
Research Site
Tianjin, China
Related Publications (1)
Zheng JP, Zhang J, Ma LJ, Chen P, Huang M, Ou XM, Zhao ZW, Jiang SJ, Cao J, Yao W. Clinical Outcomes Of Using Nebulized Budesonide As The Initial Treatment For Acute Exacerbations Of Chronic Obstructive Pulmonary Disease: A Post-Hoc Analysis. Int J Chron Obstruct Pulmon Dis. 2019 Nov 29;14:2725-2731. doi: 10.2147/COPD.S196615. eCollection 2019.
PMID: 31819404DERIVED
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Wanzhen Yao, Ph.D
Peking University Third Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 24, 2014
First Posted
January 31, 2014
Study Start
February 1, 2014
Primary Completion
August 1, 2014
Study Completion
August 1, 2014
Last Updated
June 15, 2016
Record last verified: 2016-06